Jan Hoffmann

Jan Hoffmann

Auto-generated profile, based on publicly available information

Jan Hoffmann

King's College London

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
JHJan Hoffmann
Jan Hoffmann
SMSusan P Mollan
Susan P Mollan
KPKoen Paemeleire
Koen Paemeleire
CLChristian Lampl
Christian Lampl
RJRigmor Jensen
Rigmor Jensen
ASAlexandra Sinclair
Alexandra Sinclair
Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP no identifiable cause. The aetiology remains largely unknown, however observations made in a number of recent clinical studies are increasing the understanding of the disease and now provide the basis for evidence-based treatment strategies. The Embase, CDSR, CENTRAL, DARE and MEDLINE databases were searched up to 1st June 2018. We analyzed randomized controlled trials and systematic reviews that investigate IIH. Diagnostic uncertainty, headache morbidity and visual loss are among the highest concerns of clinicians and patients in this disease area. Research in this field is infrequent due to the rarity of the disease and the lack of understanding of the underlying pathology. This European Headache Federation consensus paper provides evidence-based recommendations and practical advice on the investigation and management of IIH.

12 August 2024 in Cephalalgia
Verified
Journal Article
Open access
FPFrancesca Puledda
Francesca Puledda
SSSimona Sacco
Simona Sacco
HDHans-Christoph Diener
Hans-Christoph Diener
MAMessoud Ashina
Messoud Ashina
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
CTCristina Tassorelli
Cristina Tassorelli
Background: In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications. Methods: An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group. Results: A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained. Conclusion: Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.

5 March 2018 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
JHJan Hoffmann
Jan Hoffmann
ACAndrew Charles
Andrew Charles

11 September 2024 in Cephalalgia
Verified
Journal Article
Open access
FPFrancesca Puledda
Francesca Puledda
SSSimona Sacco
Simona Sacco
HDHans-Christoph Diener
Hans-Christoph Diener
MAMessoud Ashina
Messoud Ashina
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
CTCristina Tassorelli
Cristina Tassorelli

18 August 2021 in Cephalalgia
Verified
Journal Article
Open access
PDF file
HTHuann Lan Tan
Huann Lan Tan
JSJared G Smith
Jared G Smith
JHJan Hoffmann
Jan Hoffmann
TRTara Renton
Tara Renton
Background: Burning mouth syndrome is a chronic idiopathic intractable intraoral dysaesthesia that remains a challenge to clinicians due to its poorly understood pathogenesis and inconsistent response to various treatments. Aim: This review aimed to study the short- (≤3 months) and long-term (>3 months) effectiveness and sustainable benefit of different burning mouth syndrome treatment strategies and the associated side effects. Materials and methods: Randomised controlled trials of burning mouth syndrome treatment compared with placebo or other interventions with a minimum follow up of 2 months were searched from the PubMed, Embase and Cochrane database (published to July 2020). Results: Twenty-two studies were selected based on the inclusion and exclusion criteria and analysed. Nine categories of burning mouth syndrome treatment were identified: Anticonvulsant and antidepressant agents, phytomedicine and alpha lipoic acid supplements, low-level laser therapy, saliva substitute, transcranial magnetic stimulation, and cognitive behaviour therapy. Cognitive behaviour therapy, topical capsaicin and clonazepam, and laser therapy demonstrated favourable outcome in both short- and long-term assessment. Phytomedicines reported a short-term benefit in pain score reduction. The pooled effect of alpha lipoic acid (ALA) pain score improvement was low, but its positive effects increased in long term assessment. Conclusion: A more significant volume in terms of sample size, multi-centres, and multi-arm comparison of therapeutic agents with placebo and longitudinal follow-up studies is recommended to establish a standardised burning mouth syndrome treatment protocol. Further studies are required to assess the analgesic benefits of topical clonazepam and capsaicin, alternative medicines with neurodegenerative prevention capability and psychology support in treating burning mouth syndrome and reducing systemic adverse drug reactions. Registration International Prospective Register of Systematic Reviews (PROSPERO): Protocol ID - CRD42020160892.

26 September 2017 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
JHJan Hoffmann
Jan Hoffmann
SBSerapio M Baca
Serapio M Baca
SASimon Akerman
Simon Akerman
Vascular theories of migraine and cluster headache have dominated for many years the pathobiological concept of these disorders. This view is supported by observations that trigeminal activation induces a vascular response and that several vasodilating molecules trigger acute attacks of migraine and cluster headache in susceptible individuals. Over the past 30 years, this rationale has been questioned as it became clear that the actions of some of these molecules, in particular, calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide, extend far beyond the vasoactive effects, as they possess the ability to modulate nociceptive neuronal activity in several key regions of the trigeminovascular system. These findings have shifted our understanding of these disorders to a primarily neuronal origin with the vascular manifestations being the consequence rather than the origin of trigeminal activation. Nevertheless, the neurovascular component, or coupling, seems to be far more complex than initially thought, being involved in several accompanying features. The review will discuss in detail the anatomical basis and the functional role of the neurovascular mechanisms relevant to migraine and cluster headache.